Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Merck & Co., Inc. (MRK)
Price$148.78Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B | $41.52B | $39.12B | $42.29B | $40.12B | $39.81B | $39.50B | $42.24B | $44.08B | $47.27B | $48.05B | $45.99B | $27.43B | $23.85B | $24.20B |
| Gross profit | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B | $27.90B | $27.11B | $28.79B | $27.21B | $25.78B | $24.56B | $25.47B | $27.13B | $30.82B | $31.18B | $27.59B | $18.41B | $18.27B | $18.06B |
| Gross margin | 74.80% | 76.32% | 73.17% | 70.63% | 72.02% | 67.20% | 69.29% | 68.06% | 67.82% | 64.75% | 62.19% | 60.30% | 61.54% | 65.21% | 64.89% | 60.00% | 67.12% | 76.59% | 74.62% |
| Research & development | $15.79B | $17.94B | $30.53B | $13.55B | $12.24B | $13.40B | $9.72B | $9.75B | $10.34B | $10.26B | $6.70B | $7.18B | $7.50B | $8.17B | $8.47B | $11.11B | $5.84B | $4.80B | $4.88B |
| Operating expenses | $26.52B | $28.75B | $41.03B | $23.59B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $22.11B | $20.22B | $2.95B | $18.28B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 34.01% | 31.51% | 4.91% | 30.84% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | $28.26B | $25.71B | $6.91B | $21.32B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | 43.47% | 40.06% | 11.49% | 35.95% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | $18.25B | $17.12B | $365.0M | $14.52B | $13.05B | $7.07B | $9.84B | $6.22B | $2.39B | $3.92B | $4.44B | $11.92B | $4.40B | $6.17B | $6.27B | $861.0M | $12.90B | $7.81B | $3.28B |
| Net profit margin | 28.08% | 26.68% | 0.61% | 24.49% | 26.79% | 17.02% | 25.16% | 14.71% | 5.97% | 9.85% | 11.25% | 28.22% | 9.99% | 13.05% | 13.05% | 1.87% | 47.03% | 32.74% | 13.54% |
| Basic EPSper basic share | $7.30 | $6.76 | $0.14 | $5.73 | $5.16 | $2.79 | $3.84 | $2.34 | $0.88 | $1.42 | $1.58 | $4.12 | $1.49 | $2.03 | $2.04 | $0.28 | $5.67 | $3.65 | $1.51 |
| Diluted EPSper diluted share | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.78 | $3.81 | $2.32 | $0.87 | $1.41 | $1.56 | $4.07 | $1.47 | $2.00 | $2.02 | $0.28 | $5.65 | $3.63 | $1.49 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BlackRock, Inc. | 227M |
VANGUARD CAPITAL MANAGEMENT LLC | 161.32M |
STATE STREET CORP | 120.41M |
WELLINGTON MANAGEMENT GROUP LLP | 86.25M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 67.74M |
GEODE CAPITAL MANAGEMENT, LLC | 60.74M |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 54.37M |
MORGAN STANLEY | 48.64M |
FMR LLC | 45.44M |
JPMORGAN CHASE & CO | 43.89M |
Fisher Asset Management, LLC | 38.52M |
NORGES BANK | 36.98M |
BANK OF AMERICA CORP /DE/ | 30.54M |
NORTHERN TRUST CORP | 26.28M |
GOLDMAN SACHS GROUP INC | 22.08M |
FRANKLIN RESOURCES INC | 19.55M |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 19.55M |
Legal & General Group Plc | 18.87M |
Invesco Ltd. | 18.61M |
PRICE T ROWE ASSOCIATES INC /MD/ | 18.52M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026Form 4 | Guindo ChirfiChief Marketing Officer | SellCommon Stock | 10.0K | $121.46 | $1.21M | 60.6K |
| Feb 10, 2026Form 4 | Li Dean YExecutive VP & President, MRL | SellCommon Stock | 10.2K | $117.52 | $1.20M | 92.0K |
| Feb 9, 2026Form 4 | Guindo ChirfiChief Marketing Officer | SellCommon Stock | 10.0K | $118.41 | $1.18M | 70.6K |
| Feb 9, 2026Form 4 | Zachary JenniferEVP, General Counsel | SellCommon Stock | 38.8K | $119.15 | $4.63M | 68.9K |
| Feb 9, 2026Form 4 | Zachary JenniferEVP, General Counsel | SellCommon Stock | 56.8K | $119.15 | $6.77M | 68.9K |
Community posts
Merck licenses preclinical cancer drug for $400 million upfront
Merck ($MRK) has completed an exclusive worldwide licensing agreement with SciBrunch Therapeutics for SPR2015, an experimental oral inhibitor targeting the active form of KRAS G12D. Merck gains development, manufacturing and commercializati ...
Merck wins FDA approval for Welireg–Lenvima kidney-cancer combination
Merck ($MRK) received FDA approval for Welireg plus Lenvima as an oral treatment for adults with advanced clear-cell renal cell carcinoma after a PD-1 or PD-L1 inhibitor. The decision adds a treatment option for patients whose kidney cancer ...
Merck’s Keytruda–Padcev regimen advances toward broader European use
Merck ($MRK) received a positive European advisory opinion for Keytruda combined with Padcev before and after radical cystectomy in adults with resectable muscle-invasive bladder cancer. The recommendation also covers subcutaneous Keytruda. ...
